Skip to Main Content

Author Details

Goutham Narla
The University of Michigan Medical School ann arbor
1995
106
47
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36562288Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.Cancer Med2023
37644036Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.Nat Commun2023
36562288Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.Cancer Med2023
37437699Regulation and role of the PP2A-B56 holoenzyme family in cancer.Biochim Biophys Acta Rev Cancer2023
37166997PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.J Clin Invest2023
36788429Small-Molecule-Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death.Mol Cancer Ther2023
36455198Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation.Blood2023
37644036Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.Nat Commun2023
37437699Regulation and role of the PP2A-B56 holoenzyme family in cancer.Biochim Biophys Acta Rev Cancer2023
37166997PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.J Clin Invest2023
36788429Small-Molecule-Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death.Mol Cancer Ther2023
36455198Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation.Blood2023
35258993Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now.JCO Oncol Pract2022
36328247Biased holoenzyme assembly of protein phosphatase 2A (PP2A): From cancer to small molecules.J Biol Chem2022
34921012Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.Cancer Res2022
35258993Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now.JCO Oncol Pract2022
36328247Biased holoenzyme assembly of protein phosphatase 2A (PP2A): From cancer to small molecules.J Biol Chem2022
34921012Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.Cancer Res2022
34192314Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents.Clin Sci (Lond)2021
33568357PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.Mol Cancer Ther2021
34264540Food and science: Lessons learned from a great chef.Am J Hematol2021
33776708Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series.Case Rep Oncol2021
34145035CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis.Cancer Res2021
33986468Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis.Sci Rep2021
34192314Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents.Clin Sci (Lond)2021
34027909Genome-Wide Association Study of Pelvic Organ Prolapse Using the Michigan Genomics Initiative.Female Pelvic Med Reconstr Surg2021
34402501Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm.Clin Sci (Lond)2021
33568357PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.Mol Cancer Ther2021
33776708Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series.Case Rep Oncol2021
34402501Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm.Clin Sci (Lond)2021
33986468Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis.Sci Rep2021
34264540Food and science: Lessons learned from a great chef.Am J Hematol2021
34145035CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis.Cancer Res2021
34027909Genome-Wide Association Study of Pelvic Organ Prolapse Using the Michigan Genomics Initiative.Female Pelvic Med Reconstr Surg2021
31541192Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.Oncogene2020
32315618Selective PP2A Enhancement through Biased Heterotrimer Stabilization.Cell2020
32130915Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr<sup>307</sup> on PP2Ac.Cell Rep2020
31822503Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.J Biol Chem2020
31763993Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity.J Clin Invest2020
32482664Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis.Cancer Discov2020
32531271Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.Cancer Cell2020
32814087Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy.Cancer Lett2020
32522823A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.Cancer Res2020
33027304The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.PLoS One2020
32954276Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma.Brain Commun2020
33275593Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex.PLoS Biol2020
31541192Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.Oncogene2020
31822503Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.J Biol Chem2020
31763993Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity.J Clin Invest2020
33027304The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.PLoS One2020
  • 1 - 50 of 212

Recommended Authors

Alexandre Rosa Campos
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2015
Number of shared co-authors 0
Shruthy Suresh
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 0
Victor Olivas
University of California san francisco
Career Start Year 2012
Number of shared co-authors 1
Thibault Houles
Institute for Research in Immunology and Cancer (IRIC), Universite de Montreal
Career Start Year 2011
Number of shared co-authors 0
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Rahul K Kollipara
McDermott Center for Human Growth and Development.
Career Start Year 2010
Number of shared co-authors 2
Helen He Zhu
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Career Start Year 2009
Number of shared co-authors 0
Jason De Melo
Princess Margaret Cancer Center
Career Start Year 2009
Number of shared co-authors 0
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 4
Kurt W Fisher
University of Nebraska Medical Center
Career Start Year 2004
Number of shared co-authors 0
Genevi??ve Lavoie
Institute for Research in Immunology and Cancer (IRIC)
Career Start Year 2004
Number of shared co-authors 1
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Yongmei Feng
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2002
Number of shared co-authors 2
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 5
Ernesto Guccione
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Career Start Year 2001
Number of shared co-authors 1
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 5
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 4
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 0
Nabeel Bardeesy
Massachusetts General Hospital
Career Start Year 1992
Number of shared co-authors 10
John Easton
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 0
Suzanne Carreira
The Institute of Cancer Research
Career Start Year 1990
Number of shared co-authors 3
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 3
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 3
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 0
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 6
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 8
Massimo Loda
Weill Medical College of Cornell University
Career Start Year 1984
Number of shared co-authors 9
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 4
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 6

Collaborators

Analisa DiFeo
Co-authored papers 32
Jaya Sangodkar
University of Michigan ann arbor
Co-authored papers 29
Caitlin M O'Connor
Co-authored papers 15
Sudeh Izadmehr
Co-authored papers 13
Caroline C Farrington
Co-authored papers 11
Michael Ohlmeyer
Atux Iskay LLC
Co-authored papers 10
Matthew D Galsky
Co-authored papers 9
Sahar Mazhar
Co-authored papers 7
Alice C Levine
Co-authored papers 7
Shen Yao
Co-authored papers 7
Daniel Leonard
Co-authored papers 6
Nilesh Zaware
Co-authored papers 6
David B Kastrinsky
Co-authored papers 6
Eldad A Hod
Columbia University Irving Medical Center, New York-Presbyterian Hospital
Co-authored papers 6
Abbey L Perl
Co-authored papers 6
Daniela Schlatzer
Co-authored papers 6
Kimberly McClinch
Co-authored papers 5
David L Brautigan
Co-authored papers 5
Rosalie C Sears
Oregon Health and Science University
Co-authored papers 5
Eric Yuan
Co-authored papers 5
Martin J Walsh
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Co-authored papers 5
Rita A Avelar
Co-authored papers 5
Shozeb Haider
Co-authored papers 5
Neil S Dhawan
Co-authored papers 5
Danica D Wiredja
Co-authored papers 5
Avi Ma'ayan
Icahn School of Medicine at Mount Sinai
Co-authored papers 4
Zhizhi Wang
Co-authored papers 4
Wenqing Xu
Co-authored papers 4
Agnes Stachnik
Co-authored papers 4
Andrew M Chan
Co-authored papers 4
Release 1.2